Table 1.
Demographic and clinical parameters of the study cohort.
| All Population (n = 120) |
MACEs (−) (n = 86) |
MACEs (+) (n = 34) |
p Value |
|
|---|---|---|---|---|
| Male gender, n (%) | 68 (56.7) | 47 (54.7) | 21 (61.8) | 0.48 |
| Age, years | 77.5 ± 4.6 | 77.6 ± 4.9 | 77.2 ± 3.7 | 0.70 |
| BMI, kg/m2 | 23.1 ± 2.0 | 23.0 ± 2.0 | 23.2 ± 2.1 | 0.63 |
| Risk factors | ||||
| Hypertension, n (%) | 68 (56.7) | 53 (61.6) | 15 (44.1) | 0.08 |
| Diabetes, n (%) | 72 (60) | 50 (58.1) | 22 (64.7) | 0.51 |
| Smoking, n (%) | 16 (13.3) | 12 (14.0) | 4 (11.8) | 0.75 |
| Hyperlipidemia, n (%) | 53 (44.2) | 39 (45.3) | 14 (41.2) | 0.68 |
| CAD history, n (%) | 47 (39.2) | 35 (40.7) | 12 (35.3) | 0.59 |
| PAD, n (%) | 28 (23.3) | 22 (25.6) | 6 (17.6) | 0.35 |
| CRF history, n (%) | 23 (19.2) | 16 (18.6) | 7 (20.6) | 0.80 |
| COPD, n (%) | 53 (44.2) | 38 (44.2) | 15 (44.1) | 0.99 |
| CVA history, n (%) | 6 (5) | 3 (3.5) | 3 (8.8) | 0.23 |
| NYHA Class III-IV, n (%) | 43 (35.8) | 28 (32.6) | 15 (44.1) | 0.23 |
| Atrial fibrillation, n (%) | 20 (16.7) | 12 (14) | 8 (23.5) | 0.20 |
| Presence of BBB, n (%) | 19 (15.8) | 11 (12.8) | 8 (23.5) | 0.15 |
| Medications | ||||
| Acetylsalicylic acid, n (%) | 33 (27.5) | 26 (30.2) | 7 (20.6) | 0.29 |
| OAC, n (%) | 16 (13.3) | 10 (11.6) | 6 (17.6) | 0.38 |
| Beta-blockers, n (%) | 44 (36.7) | 34 (39.5) | 10 (29.4) | 0.30 |
| RAS blockers, n (%) | 39 (32.5) | 30 (34.9) | 9 (26.5) | 0.38 |
| Statin, n (%) | 18 (15) | 12 (14) | 6 (17.6) | 0.61 |
| Diuretic, n (%) | 34 (28.5) | 25 (29.1) | 9 (26.5) | 0.78 |
Continuous variables are presented as mean ± SD or median (IQR), nominal variables presented as frequency (%). Abbreviations: MACEs, major adverse cardiac events; BMI, body mass index; CAD, coronary artery disease; PAD, peripheral arterial disease; CRF, chronic failure; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; NYHA, New York Heart Association; BBB, bundle branch block; OAC, oral anticoagulant; RAS, renin–angiotensin system.